Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. He has extensive experience in clinical trials investigating the clinical pharmacology of antiretrovirals and TB drugs in neonates, infants, children and pregnant women. He has served as protocol chair, vice-chair, investigator and/or protocol pharmacologist on more than 25 perinatal and pediatric HIV protocols in the US, Africa, South America and Asia sponsored by NIAID, NICHD and CDC. He currently serves as co-chair of the US Perinatal HIV Guidelines Committee and is a member of the US Pediatric HIV Guidelines Committee and the WHO Pediatric Antiretroviral Working Group.
Conflict of Interest: Dr. Mirochnick has salary support through his institution for research activities from Merck, ViiV and Gilead. His wife receives salary support for research activities through her institution from ViiV. He also receives consulting fees from AstraZeneca for his serving on the DSMBs for 2 of their protocols.